The results of the Panku-Breast01 phase III clinical study for later treatment of HR+HER2 advanced breast cancer, independently developed by Baili Tianheng, were announced during the major Late-Breaking Abstract session of the conference. The research results were simultaneously listed in the main issue of “The Lancet” and published in full.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.